Francis Giles, M.D., is Professor and Chief of the Division of Hematology/Oncology within Northwestern University’s Feinberg School of Medicine, Deputy Director of the NCI-designated Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Director of the Developmental Therapeutics Institute of the Lurie Cancer Center. Dr. Giles is a leader in the full spectrum of development of novel drugs, immunotherapies, and other highly targeted approaches, including cancer-directed viruses, monoclonal antibodies, and molecularly directed agents. He has served as principal investigator on US and international First in Human, Phase I, II, and III clinical studies of many novel agents, and holds numerous patents and technology licenses. He has pioneered the use of many agents that are now in regular use as targeted therapies for patients with cancer. Among his many accolades, Dr. Giles was recently elected as a Fellow of the European Academy of Cancer Sciences. He is a Fellow of both the Royal College of Physicians of Ireland and the Royal College of Pathology (United Kingdom). He is the founder and Chairman of both the International Oncology Study Group and the Developmental Therapeutics Consortium. He has authored almost 600 peer-reviewed articles on bioscience research in leading academic journals. Dr. Giles earned his medical degree from the National University of Ireland.

Steve Davidsen, Ph.D., is Vice President, Oncology Discovery in AbbVie’s R&D organization, where he is resp
onsible for discovery and research efforts of AbbVie’s Oncology programs. Prior to AbbVie’s separation from Abbott, Dr. Davidsen served as Divisional Vice President, Cancer Research. He joined the company in 1986 as a research scientist and has held various positions of increasing responsibility in the Discovery organization. Dr. Davidsen has been a critical leader in building AbbVie’s Oncology pipeline, directing research teams and partnerships that have led to more than 55 current Oncology trials in more than 15 different cancer and tumor types.  He steered the expansion of AbbVie’s efforts in oncology biologics and translational biology and has more than 70 scientific publications across a diverse range of topics including metalloproteinase inhibitors, kinase inhibitors and the discovery of PAF antagonists. Dr. Davidsen is a member of AbbVie’s Global Pharmaceutical R&D Senior Discovery Leadership Team and Global Pharmaceutical R&D Portfolio Leadership Team. He earned his Ph.D. in organic chemistry from the University of Texas, Austin.

Moderator: Mary J.C. Hendrix, Ph.D., is the President and Director of the Stanley Manne Children’s Research Institute, and a Professor at the Robert H Lurie Comprehensive Cancer Center. Dr. Hendrix is a member of the editorial boards for 7 scientific and medical journals, including Cancer Research and the Journal of Cellular Biochemistry. She is a Past-President of FASEB (Federation of American Societies for Experimental Biology) consisting of over 100,000 members – the largest coalition of biomedical research societies in the United States. She serves on the Board of Directors for the Annenberg Center for Health Sciences, the Board of Directors for Research!America, the Board of Directors for the Chicago Council on Science & Technology, and the Board of Directors for the National Disease Research Interchange, which she chairs. Dr. Hendrix served on the Council of Councils of the National Institutes of Health, the National Cancer Institute Board of Scientific Advisors, the National Human Genome Research Institute Council, and is Co-Founder of the Virtual Naval Hospital. She has over 270 publications in biomedical research, and is the recipient of a MERIT Award from the National Cancer Institute. She earned her Ph.D. in Anatomy from George Washington University.

Sponsorship for this program was provided by AbbVie